Envestnet Asset Management’s Alder Biopharmaceuticals ALDR Stock Holding History

Envestnet Asset Management’s Portfolio ALDR Stock Details ALDR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-247	Closed	-$4K	–	3014
2018 Q2	$4K	Hold	247	–	–	﹤0.01%	2681
2018 Q1	$3K	Sell	247 -391	-61%	-$5.66K	﹤0.01%	2679
2017 Q4	$8K	Sell	638 -231	-27%	-$2.58K	﹤0.01%	2676
2017 Q3	$11K	Buy	869 +244	+39%	+$2.54K	﹤0.01%	2593
2017 Q2	$7K	Sell	625 -7	-1%	-$129	﹤0.01%	2787
2017 Q1	$13K	Buy	632 +284	+82%	+$6.29K	﹤0.01%	2746
2016 Q4	$7K	Buy	+348	New	+$9.05K	﹤0.01%	2833
2016 Q3	–	Sell	-1,175	Closed	-$29K	–	3121
2016 Q2	$29K	Sell	1,175 -126	-10%	-$3.41K	﹤0.01%	2896
2016 Q1	$32K	Sell	1,301 -169	-11%	-$3.91K	﹤0.01%	2861
2015 Q4	$49K	Sell	1,470 -6	-0.4%	-$203	﹤0.01%	2686
2015 Q3	$48K	Buy	+1,476	New	+$62.8K	﹤0.01%	2679

Other funds holding ALDR

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Envestnet Asset Management's ALDR Position: Q3 2018 in Review

Envestnet Asset Management sold out of Alder Biopharmaceuticals (ALDR) in Q3 2018, closing a stake of 247 shares — an estimated $4K sold.

Envestnet Asset Management first reported a position in ALDR in Q3 2015 and held it in 11 quarters. The position peaked at $49K in Q4 2015. 127 funds tracked by Wall St. Rank hold ALDR as of Q3 2018.

Envestnet Asset Management reported no remaining Alder Biopharmaceuticals position as of Q3 2018 after selling out during the quarter.
Envestnet Asset Management sold 247 Alder Biopharmaceuticals shares in Q3 2018, an estimated $4K.
Envestnet Asset Management first reported a position in Alder Biopharmaceuticals in Q3 2015 and held it in 11 quarters.
Envestnet Asset Management's Alder Biopharmaceuticals position peaked at $49K in Q4 2015.
127 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q3 2018.

Based on Envestnet Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.